Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Regeneron is the second pharma group to sign ... Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.

Addison Shea is one of 40 finalists for the Science Talent Search finals in Washington, D.C., in March. Addison Shea couldn’t ...

In School Zone, Central trustees name new school; Clovis North seniors nab science awards; Fresno teachers not ready for goals?

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

Tyler Clair's sustainable method of water treatment has made him one of two MN STS Scholars Minnetonka High School senior ...